CLAIMS

1. A composition for transmucosal absorption comprising a pharmaceutically acceptable cyclobenzaprine salt and a basifying agent, wherein the composition comprises less than 9 mg of the cyclobenzaprine salt, and the cyclobenzaprine salt to basifying agent molar ratio is between 1:0.5 to 1:6.

2. The composition of claim 1, comprising 0.1 mg to 5 mg of the pharmaceutically acceptable cyclobenzaprine salt.

3. The composition of claim 1, wherein the pharmaceutically acceptable cyclobenzaprine salt is present in an amount of less than or equal to 2.4 mg.

4. The composition of claim 1, wherein the pharmaceutically acceptable cyclobenzaprine salt is present in an amount of less than or equal to 4.8 mg.

5. The composition of claim 1, wherein the pharmaceutically acceptable cyclobenzaprine salt is present in an amount of 2.8 mg.

6. The composition of claim 1, wherein the pharmaceutically acceptable cyclobenzaprine salt is present in an amount of 5.6 mg.

7. The composition of any one of claims 1-6, wherein the basifying agent is selected from the group consisting of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate, sodium carbonate, sodium bicarbonate, calcium carbonate, calcium bicarbonate, TRIS buffer, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium carbonate, potassium bicarbonate, potassium acetate, sodium acetate, dipotassium citrate, tripotassium citrate, disodium citrate and trisodium citrate.

8. The composition of any one of claims 1-7, wherein the transmucosal absorption is oral absorption.

9. The composition of claim 8, wherein the oral absorption is sublingual absorption.

10. The composition of claim 9, wherein the composition is selected from the group consisting of a sublingual tablet, a sublingual film, a sublingual powder, and a sublingual spray solution.

11. The composition of any one of claims 1-8, wherein the transmucosal absorption is buccal absorption.

12. The composition of claim 11, wherein the composition is selected from the group consisting of a buccal tablet, a lozenge, a buccal powder, and a buccal spray solution.

13. The composition of any one of claims 1-7, wherein the transmucosal absorption is intranasal absorption.

14. The composition of claim 13, wherein the composition is a nasal spray solution.

15. The composition of any one of claims 1-7, wherein the transmucosal absorption is pulmonary absorption.

16. The composition of claim 15, wherein the composition is selected from the group consisting of an aerosolized composition and an inhalable dry powder.

17. Use of a composition of any one of claims 1-7 in the manufacture of a medicament for transmucosal absorption for treating a disease or condition in an individual in need thereof, wherein the disease or condition is post-traumatic stress disorder (PTSD), fibromyalgia, depression, traumatic brain injury, sleep disorder, non-restorative sleep, chronic pain, muscle spasm, or anxiety disorder.

18. The use of claim 17, wherein the disease or condition is post-traumatic stress disorder (PTSD).

19. The use of claim 18, wherein the disease or condition is the development, initiation, consolidation, or perpetuation of PTSD following a traumatic event.

20. The use of any one of claims 17-19, wherein the transmucosal absorption is sublingual absorption.

21. The use of claim 20, wherein the medicament is selected from the group consisting of a sublingual tablet, a sublingual film, a sublingual powder, and a sublingual spray solution.

22. The use of any one of claims 17-19, wherein the transmucosal absorption is buccal absorption.

23. The use of claim 22, wherein the medicament is selected from the group consisting of a buccal tablet, a lozenge, a buccal powder, and a buccal spray solution.

24. The use of any one of claims 17-19, wherein the transmucosal absorption is intranasal absorption.

25. The use of claim 24, wherein the medicament is a nasal spray solution.

26. The use of any one of claims 17-19, wherein the transmucosal absorption is pulmonary absorption.

27. The use of claim 26, wherein the medicament is selected from the group consisting of an aerosolized composition and an inhalable dry powder.